A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

被引：0
|
作者：
Otto Metzger Filho
Anita Giobbie-Hurder
Nancy U. Lin
Meredith Faggen
Steven Come
Thomas Openshaw
Michael Constantine
Jeanna Walsh
Rachel A. Freedman
Bryan Schneider
Harold J. Burstein
Erica L. Mayer
机构：
[1] Dana-Farber Cancer Institute,Susan F. Smith Center for Women’s Cancers
[2] Beth Israel Deaconess Medical Center,undefined
[3] Eastern Maine Medical Center,undefined
[4] Simon Cancer Center at Indiana University,undefined
[5] Dana-Farber Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 185卷
关键词：
Breast cancer; Eribulin; Adverse event; CTCAE; PRO-CTCAE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 144
页数：9
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF ERIBULIN IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER: REAL LIFE EXPERIENCE
    Zhilyaeva, Larisa
    BREAST, 2017, 36 : S53 - S54
  • [22] Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
    Shingaki, Sumito
    Kogawa, Takahiro
    Shimokawa, Mototsugu
    Haranol, Kenichi
    Naito, Yoichi
    Kusuharal, Shota
    Fujimoto, Yumi
    Matsubaral, Nobuaki
    Hosono, Ako
    Mukail, Hirofumi
    Onishi, Tatsuya
    Hojo, Takashi
    Mukohara, Toru
    JOURNAL OF CANCER, 2020, 11 (14): : 4099 - 4105
  • [23] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study.
    Yin, Yongmei
    Wu, Xinyu
    Hua, Yijia
    Sun, Chunxiao
    Liang, Yan
    Yang, Fan
    Huang, Xiang
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion
    Tamura, K.
    Takahashi, S.
    Mukohara, T.
    Tanioka, M.
    Yasojima, H.
    Ono, M.
    Naito, Y.
    Shimoi, T.
    Otani, Y.
    Kobayashi, K.
    Kogawa, T.
    Suzuki, T.
    Takase, T.
    Matsunaga, R.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S385 - S385
  • [25] A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer
    File, Danielle M.
    Abdou, Yara
    Force, Jeremy
    Moore, Dominic T.
    Anders, Carey K.
    Reeder-Hayes, Katherine
    Carey, Lisa A.
    Muss, Hyman B.
    Perou, Charles M.
    Marcom, P. Kelly
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2024, 24 (08) : 683 - 690
  • [26] Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
    Quintela-Fandino, Miguel
    Holgado, Esther
    Manso, Luis
    Morales, Serafin
    Bermejo, Begona
    Colomer, Ramon
    Apala, Juan V.
    Blanco, Raquel
    Munoz, Manuel
    Caleiras, Eduardo
    Iranzo, Vega
    Martinez, Mario
    Dominguez, Orlando
    Hornedo, Javier
    Gonzalez-Cortijo, Lucia
    Cortes, Javier
    Gasol Cudos, Ariadna
    Malon, Diego
    Lopez-Alonso, Antonio
    Moreno-Ortiz, Maria C.
    Mouron, Silvana
    Manes, Santos
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [27] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Barrios, Carlos H.
    Liu, Mei-Ching
    Lee, Soo Chin
    Vanlemmens, Laurence
    Ferrero, Jean-Marc
    Tabei, Toshio
    Pivot, Xavier
    Iwata, Hiroji
    Aogi, Kenjiro
    Lugo-Quintana, Roberto
    Harbeck, Nadia
    Brickman, Marla J.
    Zhang, Ke
    Kern, Kenneth A.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) : 121 - 131
  • [28] Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
    Miguel Quintela-Fandino
    Esther Holgado
    Luis Manso
    Serafin Morales
    Begoña Bermejo
    Ramon Colomer
    Juan V. Apala
    Raquel Blanco
    Manuel Muñoz
    Eduardo Caleiras
    Vega Iranzo
    Mario Martinez
    Orlando Dominguez
    Javier Hornedo
    Lucia Gonzalez-Cortijo
    Javier Cortes
    Ariadna Gasol Cudos
    Diego Malon
    Antonio Lopez-Alonso
    María C. Moreno-Ortíz
    Silvana Mouron
    Santos Mañes
    Breast Cancer Research, 22
  • [29] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Carlos H. Barrios
    Mei-Ching Liu
    Soo Chin Lee
    Laurence Vanlemmens
    Jean-Marc Ferrero
    Toshio Tabei
    Xavier Pivot
    Hiroji Iwata
    Kenjiro Aogi
    Roberto Lugo-Quintana
    Nadia Harbeck
    Marla J. Brickman
    Ke Zhang
    Kenneth A. Kern
    Miguel Martin
    Breast Cancer Research and Treatment, 2010, 121 : 121 - 131
  • [30] Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute
    Yardley, D. A.
    Hainsworth, J. D.
    Shastry, M.
    Finney, L.
    Burns, H. A.
    CANCER RESEARCH, 2012, 72
12345